Brief: Medicenna Receives Regulatory Clearance To Expand Phase 1/2 Ability Study Of MDNA11 To Canada

Medicenna Therapeutics

17/12/2021 12:13

Dec 17 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA RECEIVES REGULATORY CLEARANCE TO EXPAND PHASE 1/2 ABILITY STUDY
OF
MDNA11 TO CANADA
    * MEDICENNA THERAPEUTICS CORP - PRELIMINARY UPDATE ON SAFETY AND PK/PD DATA
EXPECTED BY YEAR-END 2021
    * MEDICENNA THERAPEUTICS CORP - ADDITIONAL SAFETY, PK/PD, BIOMARKER AND
INITIAL
EFFICACY DATA FROM TRIAL IS EXPECTED IN MID-2022
    * MEDICENNA THERAPEUTICS CORP - ABILITY STUDY IS CURRENTLY ONGOING AT
CLINICAL
TRIAL SITES IN AUSTRALIA
    * MEDICENNA THERAPEUTICS CORP - COMPANY MAY ALSO PURSUE TRIAL'S EXPANSION
INTO
UNITED KINGDOM, IF REQUIRED

Source text for Eikon:  ID:nGNX92FTlL 
Further company coverage:  MDNA.TO